Sendai Virus As a Backbone for Vaccines Against RSV and Other Human Paramyxoviruses

Overview

Journal Expert Rev Vaccines

Date 2015 Dec 10

PMID 26648515

Citations 23

Authors

Charles J Russell

Julia L Hurwitz

Affiliations

Soon will be listed here.

Abstract

Human paramyxoviruses are the etiological agents for life-threatening respiratory virus infections of infants and young children. These viruses, including respiratory syncytial virus (RSV), the human parainfluenza viruses (hPIV1-4) and human metapneumovirus (hMPV), are responsible for millions of serious lower respiratory tract infections each year worldwide. There are currently no standard treatments and no licensed vaccines for any of these pathogens. Here we review research with which Sendai virus, a mouse parainfluenza virus type 1, is being advanced as a Jennerian vaccine for hPIV1 and as a backbone for RSV, hMPV and other hPIV vaccines for children.

Citing Articles

Characterization of a recombinant Sendai virus vector encoding the small ruminant lentivirus gag-P25: antiviral properties in vitro and transgene expression in sheep.

Gomez A, Glaria I, Moncayola I, Echeverria I, Arrizabalaga J, Rodriguez-Largo A Vet Res. 2025; 56(1):51.

PMID: 40055839 PMC: 11889777. DOI: 10.1186/s13567-025-01475-2.

SERINC5 counters retroviruses and non-retroviruses.

Yu J, Liu C, Qu X, Gao X, Liu Y Front Cell Infect Microbiol. 2025; 14:1516806.

PMID: 39902183 PMC: 11788155. DOI: 10.3389/fcimb.2024.1516806.

Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.

Bouazzaoui A, Abdellatif A Vaccine X. 2024; 19:100500.

PMID: 38873639 PMC: 11170481. DOI: 10.1016/j.jvacx.2024.100500.

Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.

Loo C, Lee W, Zhou Q Pharm Res. 2023; 40(5):1015-1036.

PMID: 37186073 PMC: 10129308. DOI: 10.1007/s11095-023-03520-1.

Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.

Cordeiro A, Patil-Sen Y, Shivkumar M, Patel R, Khedr A, Elsawy M Pharmaceutics. 2021; 13(12).

PMID: 34959372 PMC: 8707864. DOI: 10.3390/pharmaceutics13122091.

References

Skiadopoulos M, Surman S, Riggs J, Elkins W, St Claire M, Nishio M . Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology. 2002; 297(1):153-60. DOI: 10.1006/viro.2002.1416. View

Ishii H, Matano T . Development of an AIDS vaccine using Sendai virus vectors. Vaccine. 2015; 33(45):6061-5. DOI: 10.1016/j.vaccine.2015.06.114. View

Murawski M, McGinnes L, Finberg R, Kurt-Jones E, Massare M, Smith G . Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2009; 84(2):1110-23. PMC: 2798376. DOI: 10.1128/JVI.01709-09. View

Karron R, Thumar B, Schappell E, Surman S, Murphy B, Collins P . Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine. 2011; 30(26):3975-81. PMC: 3509782. DOI: 10.1016/j.vaccine.2011.12.022. View

Parker J, Whiteman M, Richter C . Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents. Infect Immun. 1978; 19(1):123-30. PMC: 414057. DOI: 10.1128/iai.19.1.123-130.1978. View

Glenn G, Fries L, Thomas D, Smith G, Kpamegan E, Lu H . A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. J Infect Dis. 2015; 213(3):411-22. DOI: 10.1093/infdis/jiv406. View

Edwards K, Zhu Y, Griffin M, Weinberg G, Hall C, Szilagyi P . Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368(7):633-43. PMC: 3662802. DOI: 10.1056/NEJMoa1204630. View

Scheid A, Choppin P . Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus. Virology. 1974; 57(2):475-90. DOI: 10.1016/0042-6822(74)90187-1. View

York I, Rock K . Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996; 14:369-96. DOI: 10.1146/annurev.immunol.14.1.369. View

10.

McLellan J, Chen M, Leung S, Graepel K, Du X, Yang Y . Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7. PMC: 4459498. DOI: 10.1126/science.1234914. View

11.

Anderson L . Respiratory syncytial virus vaccine development. Semin Immunol. 2013; 25(2):160-71. DOI: 10.1016/j.smim.2013.04.011. View

12.

Lamb R, Mahy B, Choppin P . The synthesis of sendai virus polypeptides in infected cells. Virology. 1976; 69(1):116-31. DOI: 10.1016/0042-6822(76)90199-9. View

13.

Anderson L, Dormitzer P, Nokes D, Rappuoli R, Roca A, Graham B . Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013; 31 Suppl 2:B209-15. PMC: 3919153. DOI: 10.1016/j.vaccine.2012.11.106. View

14.

Huang R, Rott R, WAHN K, Klenk H, Kohama T . The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology. 1980; 107(2):313-9. DOI: 10.1016/0042-6822(80)90299-8. View

15.

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

16.

Hurwitz J . Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J. 2008; 27(10 Suppl):S126-8. DOI: 10.1097/INF.0b013e318168b780. View

17.

Shinoff J, OBrien K, Thumar B, Shaw J, Reid R, Hua W . Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis. 2008; 198(7):1007-15. DOI: 10.1086/591460. View

18.

Ali A, Nayak D . Assembly of Sendai virus: M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein. Virology. 2000; 276(2):289-303. DOI: 10.1006/viro.2000.0556. View

19.

Srinivasan A, Wang C, Yang J, Shenep J, Leung W, Hayden R . Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(10):1520-7. PMC: 4936785. DOI: 10.1016/j.bbmt.2011.03.001. View

20.

Zhan X, Hurwitz J, Krishnamurthy S, Takimoto T, Boyd K, Scroggs R . Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine. 2007; 25(52):8782-93. PMC: 2238687. DOI: 10.1016/j.vaccine.2007.10.038. View